Recent advances in defining the genetic mechanisms of disease causation and modification in autosomal dominant polycystic kidney disease (ADPKD) have helped to explain some extreme disease manifestations and other phenotypic variability. Studies of the ADPKD proteins, polycystin-1 and -2, and the development and characterization of animal models that better mimic the human disease, have also helped us to understand pathogenesis and facilitated treatment evaluation. In addition, an improved understanding of aberrant downstream pathways in ADPKD, such as proliferation/secretion-related signaling, energy metabolism, and activated macrophages, in which cAMP and calcium changes may play a role, is leading to the identification of therapeutic targets. Finally, results from recent and ongoing preclinical and clinical trials are greatly improving the prospects for available, effective ADPKD treatments.
Peter C. Harris, Vicente E. Torres
Title and authors | Publication | Year |
---|---|---|
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease
L Cebotaru, Q Liu, MK Yanda, C Boinot, P Outeda, DL Huso, T Watnick, WB Guggino, V Cebotaru |
Kidney International | 2016 |
Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model
P Zhu, CJ Sieben, X Xu, PC Harris, X Lin |
Human Molecular Genetics | 2016 |
Transcriptome analysis reveals manifold mechanisms of cyst development in ADPKD
RM de Almeida, SG Clendenon, WG Richards, M Boedigheimer, M Damore, S Rossetti, PC Harris, BS Herbert, WM Xu, A Wandinger-Ness, HH Ward, JA Glazier, RL Bacallao |
Human genomics | 2016 |
Six2creFrs2α knockout mice are a novel model of renal cystogenesis
P Puri, D Bushnell, CM Schaefer, CM Bates |
Scientific Reports | 2016 |
Heterotrimeric G protein signaling in polycystic kidney disease
T Hama, F Park |
Physiological genomics | 2016 |
Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context
WN Leonhard, H Happe, DJ Peters |
Journal of the American Society of Nephrology : JASN | 2016 |
Effect of resveratrol on progression of polycystic kidney disease: a case of cautious optimism
H Moradi, ND Vaziri |
Nephrology Dialysis Transplantation | 2016 |
Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial
MV Irazabal, KZ Abebe, KT Bae, RD Perrone, AB Chapman, RW Schrier, AS Yu, WE Braun, TI Steinman, PC Harris, MF Flessner, VE Torres |
Nephrology Dialysis Transplantation | 2016 |
Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease
WN Leonhard, SJ Kunnen, AJ Plugge, A Pasternack, SB Jianu, K Veraar, F Bouazzaoui, WM Hoogaars, P Dijke, MH Breuning, ED Heer, O Ritvos, DJ Peters |
Journal of the American Society of Nephrology : JASN | 2016 |
Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells
L Stephanis, A Bonon, K Varani, G Lanza, R Gafà, P Pinton, M Pema, S Somlo, A Boletta, G Aguiari |
Clinical and Experimental Nephrology | 2016 |
Virtual-tissue computer simulations define the roles of cell adhesion and proliferation in the onset of kidney cystic disease
JM Belmonte, SG Clendenon, GM Oliveira, MH Swat, EV Greene, S Jeyaraman, JA Glazier, RL Bacallao |
Molecular biology of the cell | 2016 |
The polycystins are modulated by cellular oxygen-sensing pathways and regulate mitochondrial function
V Padovano, IY Kuo, LK Stavola, HR Aerni, BJ Flaherty, HC Chapin, M Ma, S Somlo, A Boletta, BE Ehrlich, J Rinehart, MJ Caplan, KE Mostov |
Molecular biology of the cell | 2016 |
ADPKD: clinical issues before and after renal transplantation
P Messa, CM Alfieri, E Montanari, M Ferraresso, R Cerutti |
Journal of Nephrology | 2016 |
Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease
D Zittema, IB Versteeg, RT Gansevoort, H Goor, E Heer, KA Veraar, DJ Peters, E Meijer |
American Journal of Nephrology | 2016 |
New Insights into the Molecular Mechanisms Targeting Tubular Channels/Transporters in PKD Development
M Wu, S Yu |
Kidney Diseases | 2016 |
Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists
SM Flaig, VH Gattone, BL Blazer-Yost |
Journal of Translational Internal Medicine | 2016 |
Clinical Manifestation and Management of ADPKD in Western Countries
C Sommerer, M Zeier |
Kidney Diseases | 2016 |
The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China
C Xue, CC Zhou, M Wu, CL Mei |
Kidney Diseases | 2016 |
The native TRPP2-dependent channel of murine renal primary cilia
SJ Kleene, NK Kleene |
American journal of physiology. Renal physiology | 2016 |
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial
MV Irazabal, JD Blais, RD Perrone, RT Gansevoort, AB Chapman, O Devuyst, E Higashihara, PC Harris, W Zhou, J Ouyang, FS Czerwiec, VE Torres |
Kidney International Reports | 2016 |